Compound News and Research

RSS

Skinvisible, Novartis enter agreement for technical feasibility study

Skinvisible Pharmaceuticals, has entered into a feasibility agreement with Novartis Pharma AG. Under the agreement Skinvisible will assess the technical feasibility of a topical formulation with an undisclosed compound utilizing its proprietary Invisicare polymer delivery system.

2 Feb 2011

Trained dog sniffs out colon cancer with 98% accuracy

For the study the researchers at Kyushu University trained an 8-year-old female Labrador retriever named Marine who was given breath and stool samples of 306 patients, collected right before they received colonoscopies.

2 Feb 2011

Research discovers new role of TRPV1 receptors in regulation of locomotor activity

Research by a Barrow Neurological Institute scientist on the thermoregulatory effects of a receptor more commonly studied for its role in pain is the cover story in the Feb. 2 issue of the Journal of Neuroscience.

2 Feb 2011

New compound appears to prevent pain crises in sickle cell disease: GHSU

A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.

1 Feb 2011

Painless, noninvasive biopsies with smart laser technology

Biopsies in the future may be painless and noninvasive, thanks to smart laser technology being developed at Michigan State University.

1 Feb 2011

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells.

1 Feb 2011

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

Antibiotic may help in development of new anti-cancer agents: Researchers

An antibiotic known for its immunosuppressive functions could also point the way to the development of new anti-cancer agents, researchers at the Indiana University School of Medicine have reported.

28 Jan 2011

USDA decision on genetically engineered alfalfa ends as a surrender to business for the biotech industry

Following are the comments of Senator Patrick Leahy (D-Vt.) and Congressman Peter DeFazio (D-Ore.) on USDA's announcement Thursday that the agency will completely remove current regulations that limit use of genetically engineered (GE) alfalfa, a key commodity in dairy farming, including organic dairy farming, making alfalfa the first perennial GE crop approved for widespread planting.

28 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

McGill, GSK enter collaborative research agreement on cystic fibrosis

McGill University and GlaxoSmithKline plc have signed a collaboration agreement to develop a potential breakthrough approach to treat cystic fibrosis, a fatal genetic disease. The trans-Atlantic effort between researchers from McGill's Faculty of Medicine and their GSK collaborators in the UK, will focus on developing molecules that could treat the disease by correcting the dysfunction caused by the mutated gene.

28 Jan 2011

Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

Receptos, announced today that their highly selective sphingosine-1-phosphate receptor 1 agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study.

28 Jan 2011

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

27 Jan 2011

AVRF and UPEI collaboration awarded Innovation PEI Pilot and Discovery Fund grant

Atlanta Vascular Research Foundation (AVRF), together with its collaborators at the University of Prince Edward Island (UPEI), has been awarded an Innovation PEI Pilot and Discovery Fund grant by Innovation PEI. The grant is to continue research and development in combining nutraceuticals to magnify clinical benefits for the prevention and treatment of cardiovascular and metabolic diseases. The funding from this grant is $25,000.

27 Jan 2011

SRI awarded DOE grant to expand MetaCyc database and enhance Pathway Tools software

SRI International, an independent nonprofit research and development organization, announced today it has been awarded a grant by the Department of Energy (DOE) to expand its MetaCyc database and enhance its Pathway Tools software. This project will give SRI's bioinformatics tools even greater utility in the emerging area of bioenergy, or renewable energy derived from biological sources.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

AndroScience Corp., based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

25 Jan 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.

25 Jan 2011

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

25 Jan 2011

p38-targeted compounds hold promise for Alzheimer's disease treatment

Linda J. Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, has been awarded a $750,000 grant to further her research into a possible treatment for Alzheimer's disease. The grant is from the Edward N. And Della L. Thome Memorial Foundation, and was one of only eight Awards in Alzheimer's Disease Drug Discovery Research to be given in the U.S. in 2010.

25 Jan 2011

Compound News and Research

Skinvisible, Novartis enter agreement for technical feasibility study

Trained dog sniffs out colon cancer with 98% accuracy

Research discovers new role of TRPV1 receptors in regulation of locomotor activity

New compound appears to prevent pain crises in sickle cell disease: GHSU

Painless, noninvasive biopsies with smart laser technology

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

Scientist identifies natural signaling molecule that can prevent Hemophilia A

Antibiotic may help in development of new anti-cancer agents: Researchers

USDA decision on genetically engineered alfalfa ends as a surrender to business for the biotech industry

Prototype drug halts GVHD in mouse models of bone marrow transplantation

McGill, GSK enter collaborative research agreement on cystic fibrosis

Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

AVRF and UPEI collaboration awarded Innovation PEI Pilot and Discovery Fund grant

SRI awarded DOE grant to expand MetaCyc database and enhance Pathway Tools software

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

Eisai to seek marketing authorization for perampanel in the U.S. and EU

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

p38-targeted compounds hold promise for Alzheimer's disease treatment

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News